Research Progress of Imatinib Preoperative Chemotherapy in Treatment of Advanced Gastrointestinal Stromal Tumor_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

 CAOFeng ,  LIFei

Department of General Surgery, Xuanwu Hospital, Capital Medical University, Beijing 100053, China;

Corresponding?author：

LIFei, Email: feili36@ccmu.edu.cn

Keywords：

Gastrointestinal stromal tumor; Preoperative chemotherapy; Imatinib

DOI：

10.7507/1007-9424.20140222

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To discuss the role of imatinib preoperative chemotherapy in treatment of advanced gastrointestinal stromal tumor(GIST). Method The related literatures about imatinib preoperative chemotherapy for GIST were reviewed. Results Imatinib preoperative chemotherapy is an effective treatment for advanced GIST, which significantly improve the resection rate and prolong the overall survival time for patients with advanced GIST. Conclusions Preoperative imatinib treatment has good effect for metastatic or locally advanced GIST. It should be individualized by gene type of the GIST, which is deserved to be further studied.

Citation： CAOFeng, LIFei. Research Progress of Imatinib Preoperative Chemotherapy in Treatment of Advanced Gastrointestinal Stromal Tumor. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2014, 21(7): 925-929. doi: 10.7507/1007-9424.20140222 Copy

1.	?Perez EA, Livingstone AS, Franceschi D, et al. Current incidence and outcomes of gastrointestinal mesenchymal tumors including gastrointestinal stromal tumors[J]. J Am Coll Surg, 2006, 202(4):623-629.
2.	Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors[J]. Science, 1998, 279(5350):577-580.
3.	Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations ingastrointestinal stromal tumors[J]. Science, 2003, 299(5607):708-710.
4.	Hirota S, Ohashi A, Nishida T, et al. Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors[J]. Gastroenterology, 2003, 125(3): 660-667.
5.	DeMatteo RP, Ballman KV, Antonescu CR, et al. Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor:ACOSOG Z9000(Alliance) intergroup phase 2 trial[J]. Ann Surg, 2013, 258(3):422-429.
6.	Liu SL, Chen G, Zhao YP, et al. Optimized dose of imatinib for treatment of gastrointestinal stromal tumors:a meta-analysis[J]. J Dig Dis, 2013, 14(1):16-21.
7.	Rutkowski P, Gronchi A. Efficacy and economic value of adjuvant imatinib for gastrointestinal stromal tumors[J]. Oncologist, 2013, 18(6):689-696.
8.	張艷, 季峰.胃腸道間質瘤繼發耐藥機制及其處理對策研究進展[J].國際消化病雜志, 2013, 33(2):105-108.
9.	Kanda T, Ishikawa T, Hirota S, et al. Prospective observational study of imatinib therapy in Japanese patients with advanced gastrointestinal stromal tumors:long-term follow-up and second malignancy[J]. Jpn J Clin Oncol, 2012, 42(7):578-585.
10.	Linch M, Claus J, Benson C. Update on imatinib for gastrointestinal stromal tumors:duration of treatment[J]. Onco Targets Ther, 2013, 6:1011-1023.
11.	Kang G, Park YS, Jung ES, et al. Gastrointestinal stromal tumors in children and young adults:a clinicopathologic and molecular genetic study of 22 Korean cases[J]. APMIS, 2013, 121(10): 938-944.
12.	何丹, 伍曉汀.胃腸道間質瘤c-kit基因突變的研究進展[J].中國普外基礎與臨床雜志, 2013, 20(7):820-825.
13.	劉傳, 王寧, 王雅杰.伊馬替尼治療胃腸道間質瘤的繼發性耐藥機制[J].國際腫瘤學雜志, 2010, 37(12):936-939.
14.	Eisenberg BL, Trent JC. Adjuvant and neoadjuvant imatinib therapy:current role in the management of gastrointestinal stromal tumors[J]. Int J Cancer, 2011, 129(11):2533-2542.
15.	Andtbacka RH, Ng CS, Scaife CL, et al. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib[J]. Ann Surg Oncol, 2007, 14(1):14-24.
16.	DeMatteo RP, Maki RG, Singer S, et al. Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor[J]. Ann Surg, 2007, 245(3): 347-352.
17.	Rutkowski P, Gronchi A, Hohenberger P, et al. Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST): the EORTC STBSG experience[J]. Ann Surg Oncol, 2013, 20(9):2937-2943.
18.	Eisenberg BL, Harris J, Blanke CD, et al. PhaseⅡtrial of neoadjuvant/adjuvant imatinib mesylate(IM) for advanced primary and metastatic/recurrent operable gastrointestinal stroma tumor (GIST): early results of RTOG0132/ACRIN 6665[J]. J Surg Oncol, 2009, 99(1):42-47.
19.	Wang D, Zhang Q, Blanke CD, et al. Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/ recurrent pperable gastrointestinal stromal tumors:long-term follow-up results of radiation therapy oncology group 0132[J]. Ann Surg Oncol, 2012, 19(4):1074-1080.
20.	Hohenberger P, Oladeji O, Licht T, et al. Neoadjuvant imatinib and organ preservation in locally advanced gastrointestinal stromal tumors (GIST)[J]. J Clin Oncol(Meeting Abstracts), 2009, 27: 10550.
21.	Blesius A, Cassier PA, Bertucci F, et al. Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial[J]. BMC Cancer, 2011, 11:72.
22.	McAuliffe JC, Hunt KK, Lazar AJF, et al. A randomized, phaseⅡstudy of preoperative plus postoperative imatinib in GIST:evidence of rapid radiographic response and temporal induction of tumor cell apoptosis[J]. Ann Surg Oncol, 2009, 16(4):910-919.
23.	Xia L, Zhang MM, Ji L, et al. Resection combined with imatinib therapy for liver metastases of gastrointestinal stromal tumors[J]. Surg Today, 2010, 40(10):936-942.
24.	Fiore M, Palassini E, Fumagalli E, et al. Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors(GIST)[J]. EJSO, 2009, 35(7):739-745.
25.	Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of im atinib mesylate in advanced gastrointestinal stromal tumors[J]. N Engl J Med, 2002, 347(7):472-480.
26.	王昱, 鐘捷.胃腸道間質瘤分子靶向治療的不良反應及對策[J].國際消化病雜志, 2010, 30(2):93-96, 105.
27.	DeLuca C, Shenouda-Awad N, Haskes C, et al. Imatinib mesylate (Gleevec) induced unilateral optic disc edema[J]. Optom Vis Sci, 2012, 89(10):e16-e22.
28.	Gulati AP, Saif MW. Retinal neovascularization and hemorrhage associated with the use of imatinib (Gleevec^?) in a patient being treated for gastrointestinal stromal tumor (GIST)[J]. Anticancer Res, 2012, 32(4):1375-1377.
29.	Saad Aldin E, Mourad F, Tfayli A. Gastric antral vascular ectasia in a patient with GIST after treatment with imatinib:case report and literature review[J]. Jpn J Clin Oncol, 2012, 42(5):447-450.
30.	National Comprehensive Cancer Network. http://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf.
31.	ESMO/European Sarcoma Network Working Group. Gastrointestinal stromal tumors:ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2012, 23(Suppl 7):vii49-vii55.
32.	中國CSCO胃腸間質瘤專家委員會.中國胃腸間質瘤診斷治療專家共識(2011年版)[J].中華胃腸外科雜志, 2012, 15(3): 301-307.
33.	Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor[J]. J Clin oncol, 2003, 21(23):4342-4349.
34.	Heinrich MC, Owzar K, Corless CL, et al. Correlation of kinase geno type and clinical outcome in the north American intergroup phaseⅢtrial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor:CALGB150105 study by cancer and leukemia group B and southwest oncology group[J]. J Clin Oncol, 2008, 26(33):5360-5367.
35.	Li J, Gong JF, Li J, et al. Efficacy of imatinib dose escalation in Chinese gastrointestinal stromal tumor patients[J]. World J Gastroenterol, 2012, 21, 18(7):698-703.

1. ?Perez EA, Livingstone AS, Franceschi D, et al. Current incidence and outcomes of gastrointestinal mesenchymal tumors including gastrointestinal stromal tumors[J]. J Am Coll Surg, 2006, 202(4):623-629.
2. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors[J]. Science, 1998, 279(5350):577-580.
3. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations ingastrointestinal stromal tumors[J]. Science, 2003, 299(5607):708-710.
4. Hirota S, Ohashi A, Nishida T, et al. Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors[J]. Gastroenterology, 2003, 125(3): 660-667.
5. DeMatteo RP, Ballman KV, Antonescu CR, et al. Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor:ACOSOG Z9000(Alliance) intergroup phase 2 trial[J]. Ann Surg, 2013, 258(3):422-429.
6. Liu SL, Chen G, Zhao YP, et al. Optimized dose of imatinib for treatment of gastrointestinal stromal tumors:a meta-analysis[J]. J Dig Dis, 2013, 14(1):16-21.
7. Rutkowski P, Gronchi A. Efficacy and economic value of adjuvant imatinib for gastrointestinal stromal tumors[J]. Oncologist, 2013, 18(6):689-696.
8. 張艷, 季峰.胃腸道間質瘤繼發耐藥機制及其處理對策研究進展[J].國際消化病雜志, 2013, 33(2):105-108.
9. Kanda T, Ishikawa T, Hirota S, et al. Prospective observational study of imatinib therapy in Japanese patients with advanced gastrointestinal stromal tumors:long-term follow-up and second malignancy[J]. Jpn J Clin Oncol, 2012, 42(7):578-585.
10. Linch M, Claus J, Benson C. Update on imatinib for gastrointestinal stromal tumors:duration of treatment[J]. Onco Targets Ther, 2013, 6:1011-1023.
11. Kang G, Park YS, Jung ES, et al. Gastrointestinal stromal tumors in children and young adults:a clinicopathologic and molecular genetic study of 22 Korean cases[J]. APMIS, 2013, 121(10): 938-944.
12. 何丹, 伍曉汀.胃腸道間質瘤c-kit基因突變的研究進展[J].中國普外基礎與臨床雜志, 2013, 20(7):820-825.
13. 劉傳, 王寧, 王雅杰.伊馬替尼治療胃腸道間質瘤的繼發性耐藥機制[J].國際腫瘤學雜志, 2010, 37(12):936-939.
14. Eisenberg BL, Trent JC. Adjuvant and neoadjuvant imatinib therapy:current role in the management of gastrointestinal stromal tumors[J]. Int J Cancer, 2011, 129(11):2533-2542.
15. Andtbacka RH, Ng CS, Scaife CL, et al. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib[J]. Ann Surg Oncol, 2007, 14(1):14-24.
16. DeMatteo RP, Maki RG, Singer S, et al. Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor[J]. Ann Surg, 2007, 245(3): 347-352.
17. Rutkowski P, Gronchi A, Hohenberger P, et al. Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST): the EORTC STBSG experience[J]. Ann Surg Oncol, 2013, 20(9):2937-2943.
18. Eisenberg BL, Harris J, Blanke CD, et al. PhaseⅡtrial of neoadjuvant/adjuvant imatinib mesylate(IM) for advanced primary and metastatic/recurrent operable gastrointestinal stroma tumor (GIST): early results of RTOG0132/ACRIN 6665[J]. J Surg Oncol, 2009, 99(1):42-47.
19. Wang D, Zhang Q, Blanke CD, et al. Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/ recurrent pperable gastrointestinal stromal tumors:long-term follow-up results of radiation therapy oncology group 0132[J]. Ann Surg Oncol, 2012, 19(4):1074-1080.
20. Hohenberger P, Oladeji O, Licht T, et al. Neoadjuvant imatinib and organ preservation in locally advanced gastrointestinal stromal tumors (GIST)[J]. J Clin Oncol(Meeting Abstracts), 2009, 27: 10550.
21. Blesius A, Cassier PA, Bertucci F, et al. Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial[J]. BMC Cancer, 2011, 11:72.
22. McAuliffe JC, Hunt KK, Lazar AJF, et al. A randomized, phaseⅡstudy of preoperative plus postoperative imatinib in GIST:evidence of rapid radiographic response and temporal induction of tumor cell apoptosis[J]. Ann Surg Oncol, 2009, 16(4):910-919.
23. Xia L, Zhang MM, Ji L, et al. Resection combined with imatinib therapy for liver metastases of gastrointestinal stromal tumors[J]. Surg Today, 2010, 40(10):936-942.
24. Fiore M, Palassini E, Fumagalli E, et al. Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors(GIST)[J]. EJSO, 2009, 35(7):739-745.
25. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of im atinib mesylate in advanced gastrointestinal stromal tumors[J]. N Engl J Med, 2002, 347(7):472-480.
26. 王昱, 鐘捷.胃腸道間質瘤分子靶向治療的不良反應及對策[J].國際消化病雜志, 2010, 30(2):93-96, 105.
27. DeLuca C, Shenouda-Awad N, Haskes C, et al. Imatinib mesylate (Gleevec) induced unilateral optic disc edema[J]. Optom Vis Sci, 2012, 89(10):e16-e22.
28. Gulati AP, Saif MW. Retinal neovascularization and hemorrhage associated with the use of imatinib (Gleevec^?) in a patient being treated for gastrointestinal stromal tumor (GIST)[J]. Anticancer Res, 2012, 32(4):1375-1377.
29. Saad Aldin E, Mourad F, Tfayli A. Gastric antral vascular ectasia in a patient with GIST after treatment with imatinib:case report and literature review[J]. Jpn J Clin Oncol, 2012, 42(5):447-450.
30. National Comprehensive Cancer Network. http://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf.
31. ESMO/European Sarcoma Network Working Group. Gastrointestinal stromal tumors:ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2012, 23(Suppl 7):vii49-vii55.
32. 中國CSCO胃腸間質瘤專家委員會.中國胃腸間質瘤診斷治療專家共識(2011年版)[J].中華胃腸外科雜志, 2012, 15(3): 301-307.
33. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor[J]. J Clin oncol, 2003, 21(23):4342-4349.
34. Heinrich MC, Owzar K, Corless CL, et al. Correlation of kinase geno type and clinical outcome in the north American intergroup phaseⅢtrial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor:CALGB150105 study by cancer and leukemia group B and southwest oncology group[J]. J Clin Oncol, 2008, 26(33):5360-5367.
35. Li J, Gong JF, Li J, et al. Efficacy of imatinib dose escalation in Chinese gastrointestinal stromal tumor patients[J]. World J Gastroenterol, 2012, 21, 18(7):698-703.

Previous Article
Clinical Application of Enteral Microecopharmaceutics Immunonutrition in The Perioperation of Colorectal Cancer

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Research Progress of Imatinib Preoperative Chemotherapy in Treatment of Advanced Gastrointestinal Stromal Tumor

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Format

Content